|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.67 - 21.38|
|52 Week Range||7.12 - 21.81|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||106.24|
|Forward Dividend & Yield||0.01 (0.08%)|
|1y Target Est||N/A|
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Clinuvel Pharmaceuticals Limited's (ASX:CUV) P/E ratio and reflect on what it tells us about the company's share...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Clinuvel Pharmaceuticals Limited (ASX:CUV), then you'll have to look at the makeup of...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in accordance with 21 CFR.
MELBOURNE, Australia and SINGAPORE, Dec. 19, 2018 -- SUMMARY Phase II study in vitiligo, a treatment-resistant disease1n=21, patients of Asian ethnicity, darker skin.
The direct benefit for Clinuvel Pharmaceuticals Limited (ASX:CUV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...